지에스메디칼

비상장계속사업자

GS MEDICAL

신민식

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

지에스메디칼

Business Reg. No. 1148621778 · CEO 신민식

I.Investment Overview

Target지에스메디칼 (1148621778)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명지에스메디칼
영문명GS MEDICAL
대표자신민식
사업자등록번호1148621778
법인등록번호1101112603044
설립일2002.09.10
종업원수159명

V.Workforce

159

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW1822021211.72022247202328520243612025
영업이익100M KRW6.6202121.8202222.6202345.3202446.82025
순이익100M KRW7.4202110.3202211.2202321202440.72025
Item20252024202320222021
자산총계611.6억원488.2억원460.9억원454.9억원445.9억원
부채총계216억원133.4억원127.1억원132.2억원133.5억원
자본총계395.5억원354.8억원333.8억원322.6억원312.3억원
매출액361억원285억원247억원211.7억원182억원
영업이익46.8억원45.3억원22.6억원21.8억원6.6억원
순이익40.7억원21억원11.2억원10.3억원7.4억원

VII.Financial Ratios

FY2025 basis

12.95%

영업이익률

11.27%

순이익률

6.65%

ROA

10.29%

ROE

54.62%

부채비율

64.68%

자기자본비율

VIII.R&D Activity

Fields 보건의료 · 보건의료 > 의료기기 · 보건의료 > 임상의학

Keywords 추간체유합보형재, 3차원인쇄, 주입형, 유한요소해석, 삼차원 프린팅

YearProjectsPapersPatents
2024002
2023112
2022334
2021449
2020414
2019224
2018205
2017211
2016105
2015200
2014300
2013200

IX.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

지에스메디칼 투심보고서 | Alpha Lenz